The Lancet

@thelancet.com

Welcome to The Lancet, one of the world’s leading medical journals, published weekly since 1823. 🌐 thelancet.com

From recent medical breakthroughs to science policy & social commentary: in @thelancet.com Voice Podcast, researchers, policymakers & practitioners unravel stories of groundbreaking health & clinical research, exploring the implications for the health of everyone spkl.io/6332071qTw

Multimedia | Podcasts | The Lancet Voice

If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password

spkl.io

Once rapidly fatal diseases without approved therapeutic options, systemic amyloidoses are now highly treatable. A new Review summarises treatment advancements and future directions in systemic light chain and transthyretin amyloidosis: spkl.io/633277KhbB

Human body with annotations showing potential organs or systems involved by AL or ATTR amyloidosis. Red colour indicates organs or systems mostly or uniquely involved by AL amyloidosis. Green colour indicates those mostly or uniquely involved by ATTRwt amyloidosis. Blue colour indicates sites of clinical presentation common to both. AL=light chain amyloidosis. ATTR=transthyretin amyloidosis. ATTRv=transthyretin amyloidosis variant. ATTRwt=transthyretin amyloidosis wild-type. *Also common in ATTRv. Copyright: 2026 Elsevier Ltd. All rights are reserved.

The optimal duration of dual antithrombotic therapy after percutaneous coronary intervention (PCI) in patients with atrial fibrillation remains uncertain. A recent study compared the efficacy and safety of 1-month versus 12-month dual antithrombotic therapy: spkl.io/633217KhVl

Kaplan–Meier analysis of the primary efficacy and safety endpoints. (A) The incidence of the primary efficacy endpoint, defined as a composite of all-cause death or thromboembolic events (myocardial infarction, definite stent thrombosis, stroke, or systemic embolism). (B) The primary safety endpoint, defined as bleeding (International Society on Thrombosis and Haemostasis major or clinically relevant non-major bleeding). Percentages are Kaplan–Meier estimates at 12 months (day 360). Hazard ratios compare the 1-month dual therapy group with the 12-month dual therapy group and were estimated using Cox proportional-hazards models with follow-up censored at day 360. PCI=percutaneous coronary intervention. Copyright: 2026 Elsevier Ltd. All rights are reserved.

"One of the biggest stories this week wasn't about a drug. It was about something far more familiar..." Lancet authors join our Editors to discuss highlights from #AAIC2026 & what excites them about the future of Alzheimer's Disease & dementia research. 🎧 Listen now: spkl.io/633277K7eS

Promotional card for The Lancet Pulse podcast. Concentric circles on a blue background.

Amyloidosis care has changed dramatically in the last decade. New therapies, better diagnosis, and multidisciplinary collaboration have improved outcomes—but access remains unequal. What can other rare diseases learn from this progress? Our Editorial: tinyurl.com/4ab7nhtp

Learning from a decade of progress in amyloidosis

Improving outcomes for people with rare diseases is a major challenge, but it is possible. Amyloidosis is a heterogeneous group of rare disorders in which amyloid (misfolded protein deposits) accumula...

tinyurl.com

Psoriasis is a common, chronic skin disease affecting more than 60 million individuals worldwide. In a new Seminar, authors provide an updated survey of current knowledge on psoriasis, its clinical management, and key future challenges: spkl.io/633247Kmmj

Figure 2: Pathophysiological features of psoriasis. (A) Characteristic
histopathological features of plaque psoriasis. Key histological features include marked epidermal thickening (acanthosis) with characteristic rounded appearance of ridges extending into the dermis (rete ridges), absent granular cell layer, and nuclear retention within the stratum corneum (parakeratosis). Diagnostic findings include neutrophilic aggregates within the stratum corneum forming Munro’s micro-abscesses. Characteristic dermal findings include dilated, tortuous capillaries within elongated dermal papillae and prominent perivascular lymphocytic infiltrates. (B) Key immunopathological cells and mediators of plaque psoriasis.

Mental disorders are leading contributors to disease burden among young people. A new study in @lancetrh-wpac.bsky.social provides current estimates of prevalence, patterns, severity, and profiles of mental disorders among Australians aged 16–24. Find out more: tinyurl.com/2t6849am

Rates and impact of mental disorders among Australian youth: prevalence, severity, and trends from two national psychiatric surveys

Mental disorders among Australian youth have increased markedly since 2007, with greater severity and functional impairment.

tinyurl.com

Who owns cardiometabolic disease? Many people with interconnected conditions navigate multiple clinics and care plans. Our latest Editorial discusses whether it's time to rethink how cardiometabolic care is organised. Read more: spkl.io/633217JI79

Quote from The Lancet's July 25, 2026 Editorial. Quote reads: “Most patients do not need another appointment; they need fewer, better-owned decisions.”

📣 Save the date: 18 September 2026! Join the inaugural Gustave Roussy–Lancet Lecture Series on Cancer Breakthroughs to explore personalised cancer prevention with Prof. Timothy R. Rebbeck. Join in Paris or online at 17:00 CEST. Register: spkl.io/633237yT1P

Register to attend the Gustave Roussy-Lancet Lecture Series on Sept 18. Copyright: Gustave Roussy.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial spkl.io/633277y0Iv

Kaplan–Meier analysis of the primary efficacy and safety endpoints. (A) The incidence of the primary efficacy endpoint, defined as a composite of all-cause death or thromboembolic events (myocardial infarction, definite stent thrombosis, stroke, or systemic embolism). (B) The primary safety endpoint, defined as bleeding (International Society on Thrombosis and Haemostasis major or clinically relevant non-major bleeding). Percentages are Kaplan–Meier estimates at 12 months (day 360). Hazard ratios compare the 1-month dual therapy group with the 12-month dual therapy group and were estimated using Cox proportional-hazards models with follow-up censored at day 360. PCI=percutaneous coronary intervention. Copyright: 2026 Elsevier Ltd. All rights are reserved.

How will AI change the NHS? The NHS is rolling out AI triage tools & ambient scribes across general practice — Niall Boyce & Chloe Wilson discuss in a new episode of #LancetVoice 🎧 Listen now: spkl.io/633277yNQD

How will AI change the NHS? | The Lancet Voice

Can an algorithm decide who sees a doctor first — and what happens when it gets the call wrong? The NHS is rolling out AI triage tools and ambient scribes across general practice, promising to shorten waiting lists and free up clinician time. In this episode of The Lancet Voice, host Niall Boyce and Chloe Wilson, senior editor at The Lancet, cast a questioning eye over the initiative. Chloe raises concerns about AI triage — including the risk of downgrading seemingly innocuous but important symptoms — and questions whether AI in health care is adding efficiency, or simply cutting costs. The hosts also examine ambient scribes in the consulting room, discussing how AI scribes may change clinical practice, or even deskill physicians. The issue isn't whether AI can help the NHS — it's whether we're asking it to do the right things, and if we are implementing it in the right way. Let us know your thoughts in the comments! The Lancet Voice is part of the Lancet Group podcast offering.  Editorial team: Niall Boyce, Miriam Sabin, Jessamy Bagenal, Richard Horton, and Gavin Cleaver Podcast editing: Matteo Simonetti Visit http://spkl.io/633247yNQ6 learn more about our multimedia offering.  Find the best science for better lives at thelancet.comFollow us today at...http://spkl.io/633257yNQB

spkl.io